|
Schizophrenia
|
0.620 |
GeneticVariation
|
disease |
GWASCAT |
Genome-Wide Association Study Detected Novel Susceptibility Genes for Schizophrenia and Shared Trans-Populations/Diseases Genetic Effect.
|
30285260 |
2019 |
|
Schizophrenia
|
0.620 |
Biomarker
|
disease |
BEFREE |
Additionally, MK may contribute to cancer development and pathogenesis of neurodegenerative disorders and schizophrenia.
|
29164967 |
2018 |
|
Schizophrenia
|
0.620 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia.
|
28540026 |
2017 |
|
Schizophrenia
|
0.620 |
Biomarker
|
disease |
PSYGENET |
Genetic variation in a region on chromosome 11 that contains the candidate genes AMBRA1, DGKZ, CHRM4 and MDK was significantly associated with SCZ in the combined sample (n=11 540; P=3.89 × 10(-9), odds ratio (OR)=1.25).
|
21747397 |
2012 |
|
Schizophrenia
|
0.620 |
Biomarker
|
disease |
BEFREE |
Genetic variation in a region on chromosome 11 that contains the candidate genes AMBRA1, DGKZ, CHRM4 and MDK was significantly associated with SCZ in the combined sample (n=11 540; P=3.89 × 10(-9), odds ratio (OR)=1.25).
|
21747397 |
2012 |
|
Schizophrenia
|
0.620 |
Biomarker
|
disease |
MGD |
Dopaminergic hypofunctions and prepulse inhibition deficits in mice lacking midkine.
|
19217924 |
2009 |
|
Schizophrenia
|
0.620 |
Biomarker
|
disease |
MGD |
Mice doubly deficient in the midkine and pleiotrophin genes exhibit deficits in the expression of beta-tectorin gene and in auditory response.
|
16619002 |
2006 |
|
Schizophrenia
|
0.620 |
Biomarker
|
disease |
MGD |
Midkine, a heparin-binding cytokine, plays key roles in intraperitoneal adhesions.
|
15047154 |
2004 |
|
Schizophrenia
|
0.620 |
Biomarker
|
disease |
MGD |
The role of midkine and pleiotrophin in liver regeneration.
|
15482347 |
2004 |
|
Glioma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
DNA damage repair alterations modulate M2 polarization of microglia to remodel the tumor microenvironment via the p53-mediated MDK expression in glioma.
|
30773478 |
2019 |
|
Glioma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
MDK and SP1 expression in gliomas was significantly higher than in adjacent tissues and was positively correlated in glioma clinical samples and cell lines.
|
25428991 |
2015 |
|
Glioma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of MK and PTN proteins in glioma tissue were both significantly higher (both p<0.001) than those in paratumor tissues on immunohistochemistry analysis, which was confirmed by qRT-PCR analysis.
|
25001988 |
2014 |
|
Glioma
|
0.340 |
Biomarker
|
disease |
CTD_human |
Altogether, our findings identify Mdk as a pivotal factor involved in the resistance of glioma cells to THC pro-autophagic and antitumoral action, and suggest that selective targeting of the Mdk/ALK axis could help to improve the efficacy of antitumoral therapies for gliomas.
|
21233844 |
2011 |
|
Glioma
|
0.340 |
Biomarker
|
disease |
LHGDN |
In an animal experiment, Ad-MK completely eradicated midkine-positive glioma xenografts.
|
15201962 |
2004 |
|
Malignant mesothelioma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
|
28335760 |
2017 |
|
Malignant mesothelioma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate that Ad35 fiber modification of binding tropism in a midkine promoter-regulated oncolytic Ad5 vector confers transductional targeting to oncolytic adenoviruses, thereby facilitating more effective treatment of malignant mesothelioma.
|
23962292 |
2013 |
|
Malignant mesothelioma
|
0.330 |
Biomarker
|
disease |
CTD_human |
Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool.
|
23056237 |
2012 |
|
Malignant mesothelioma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that the tumor-specific midkine (Mdk) promoter could confer transcriptional targeting to oncolytic adenoviruses for effective treatment of malignant mesothelioma.
|
20635326 |
2010 |
|
Malignant Glioma
|
0.310 |
Biomarker
|
disease |
CTD_human |
Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action.
|
21233844 |
2011 |
|
Diabetic Nephropathy
|
0.310 |
Biomarker
|
disease |
CTD_human |
Our data indicate that MK plays a critical role in the tubulointerstitial inflammation associated with diabetic nephropathy through activation of the MCP-1 pathway.
|
17607302 |
2007 |
|
Diabetic Nephropathy
|
0.310 |
AlteredExpression
|
disease |
LHGDN |
Our data indicate that MK plays a critical role in the tubulointerstitial inflammation associated with diabetic nephropathy through activation of the MCP-1 pathway.
|
17607302 |
2007 |
|
Malignant Glioma
|
0.310 |
Biomarker
|
disease |
BEFREE |
These findings indicate that midkine promoter-based conditionally replicative adenovirus might be a promising new modality of gene therapy for malignant glioma.
|
15201962 |
2004 |
|
mixed gliomas
|
0.300 |
Biomarker
|
disease |
CTD_human |
Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action.
|
21233844 |
2011 |
|
Anxiety Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
We previously demonstrated that midkine-deficient (Mdk(-/-)) mice exhibited a delayed hippocampal development with impaired working memory and increased anxiety only at the age of 4 weeks.
|
19217924 |
2009 |
|
Memory Disorders
|
0.300 |
Biomarker
|
disease |
CTD_human |
Dopaminergic hypofunctions and prepulse inhibition deficits in mice lacking midkine.
|
19217924 |
2009 |